Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Provided By GlobeNewswire
Last update: Nov 6, 2024
– First Patient Dosed in ATI-2138 Phase 2a Trial in Atopic Dermatitis As Previously Announced;
Top-line Data Anticipated in First Half of 2025 –
